Terms: = Endocrine gland cancer AND PALB2, ENSG00000083093, 79728 AND Treatment
66 results:
1. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
2. A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
Jamison JK; May MS; Raufi AG; Luk L; Wong W; Mundi PS; Manji GA
Oncologist; 2024 Apr; 29(4):350-355. PubMed ID: 38394390
[TBL] [Abstract] [Full Text] [Related]
3. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
4. Targeting BRCA and palb2 in Pancreatic cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract] [Full Text] [Related]
5. Cost-Effectiveness Analysis of Screening for Pancreatic cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast cancer.
Lynce F; Robson M
Cancer Treat Res; 2023; 186():91-102. PubMed ID: 37978132
[TBL] [Abstract] [Full Text] [Related]
7. Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond.
Rein HL; Bernstein KA
DNA Repair (Amst); 2023 Oct; 130():103563. PubMed ID: 37651978
[TBL] [Abstract] [Full Text] [Related]
8. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract] [Full Text] [Related]
9. The Clinical Implications of Reversions in Patients with Advanced Pancreatic cancer and Pathogenic Variants in BRCA1, BRCA2, or palb2 after Progression on Rucaparib.
Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
[TBL] [Abstract] [Full Text] [Related]
10. Geographical, ethnic, and genetic differences in pancreatic cancer predisposition.
Liew SZH; Ng KW; Ishak NDB; Lee SY; Zhang Z; Chiang J; Ngeow JYY
Chin Clin Oncol; 2023 Jun; 12(3):27. PubMed ID: 37417291
[TBL] [Abstract] [Full Text] [Related]
11. The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
Li Y; Chen Z; Peng J; Yuan C; Yan S; Yang N; Li P; Kong B
Oncogene; 2023 Jul; 42(31):2386-2401. PubMed ID: 37391593
[TBL] [Abstract] [Full Text] [Related]
12. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.
Florou V; Elliott A; Bailey MH; Stone D; Affolter K; Soares HP; Nevala-Plagemann C; Scaife C; Walker P; Korn WM; Lou E; Shroff RT; Hosein PJ; Garrido-Laguna I
Clin Cancer Res; 2023 Sep; 29(17):3408-3417. PubMed ID: 37266563
[TBL] [Abstract] [Full Text] [Related]
13. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma.
Ryu KH; Park S; Chun JW; Cho E; Choi J; Lee DE; Shim H; Kim YH; Han SS; Park SJ; Woo SM; Kong SY
Cancer Res Treat; 2023 Oct; 55(4):1303-1312. PubMed ID: 37024097
[TBL] [Abstract] [Full Text] [Related]
14. Personalized Systemic Therapies in Hereditary cancer Syndromes.
Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
[TBL] [Abstract] [Full Text] [Related]
15. Adherence to NCCN Genetic Testing Guidelines in Pancreatic cancer and Impact on treatment.
Crowley F; Gandhi S; Rudshteyn M; Sehmbhi M; Cohen DJ
Oncologist; 2023 Jun; 28(6):486-493. PubMed ID: 36933202
[TBL] [Abstract] [Full Text] [Related]
16. Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan.
Masood A; Sarfaraz R; Zaki S; Shami A; Khaliq S; Naseem N
Cancer Biomark; 2023; 36(3):207-219. PubMed ID: 36776043
[TBL] [Abstract] [Full Text] [Related]
17. Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice.
Reinacher-Schick A; Arnold D; Venerito M; Goekkurt E; Kraeft AL; Seufferlein T
Oncol Res Treat; 2022; 45(12):752-763. PubMed ID: 36310006
[TBL] [Abstract] [Full Text] [Related]
18. Moderate-Risk Genes for Hereditary Ovarian cancers Involved in the Homologous Recombination Repair Pathway.
Abe A; Imoto I; Ueki A; Nomura H; Kanao H
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233090
[TBL] [Abstract] [Full Text] [Related]
19. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract] [Full Text] [Related]
20. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract] [Full Text] [Related]
[Next]
